Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.

<h4>Background/objectives</h4>Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival. Therefore, novel biomarkers and therapeu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bühler, Bernhard Egger
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dc7287d69a68460e8e28be95741b3bed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dc7287d69a68460e8e28be95741b3bed
record_format	dspace
spelling	oai:doaj.org-article:dc7287d69a68460e8e28be95741b3bed2021-11-25T06:23:31ZTherapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.1932-620310.1371/journal.pone.0252397https://doaj.org/article/dc7287d69a68460e8e28be95741b3bed2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252397https://doaj.org/toc/1932-6203<h4>Background/objectives</h4>Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival. Therefore, novel biomarkers and therapeutic targets are needed. In the present review, we performed a comprehensive summary of therapeutic approaches targeting the GP130/JAK/STAT3 pathway.<h4>Methods</h4>We systematically reviewed the PubMed and Embase databases for preclinical and clinical studies, from inception to October 4, 2020, on drugs targeting the GP130/JAK/STAT3 pathway. Bias assessments and qualitative analyses were performed.<h4>Results</h4>Twenty-five preclinical and nine clinical trials were included in the review. All preclinical studies reported a favorable outcome in terms of pancreatic ductal adenocarcinoma progression. Futhermore, drugs targeting the GP130/JAK/STAT3 pathway were shown to be efficient chemosensitizers. However, high publication bias was assumed. In the clinical setting, bazedoxifene and itacitinib improved patient outcomes.<h4>Conclusion</h4>Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in the treatment of pancreatic ductal adenocarcinoma and that these molecules are effective chemosensitizers. Though only a few trials have shown the efficacy in a clinical setting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic ductal adenocarcinoma and may help overcome chemotherapy resistance.Sarah PeislClaudia MellenthinLucie VignotCarmen Gonelle-GispertLeo BühlerBernhard EggerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0252397 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sarah Peisl Claudia Mellenthin Lucie Vignot Carmen Gonelle-Gispert Leo Bühler Bernhard Egger Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
description	<h4>Background/objectives</h4>Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival. Therefore, novel biomarkers and therapeutic targets are needed. In the present review, we performed a comprehensive summary of therapeutic approaches targeting the GP130/JAK/STAT3 pathway.<h4>Methods</h4>We systematically reviewed the PubMed and Embase databases for preclinical and clinical studies, from inception to October 4, 2020, on drugs targeting the GP130/JAK/STAT3 pathway. Bias assessments and qualitative analyses were performed.<h4>Results</h4>Twenty-five preclinical and nine clinical trials were included in the review. All preclinical studies reported a favorable outcome in terms of pancreatic ductal adenocarcinoma progression. Futhermore, drugs targeting the GP130/JAK/STAT3 pathway were shown to be efficient chemosensitizers. However, high publication bias was assumed. In the clinical setting, bazedoxifene and itacitinib improved patient outcomes.<h4>Conclusion</h4>Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in the treatment of pancreatic ductal adenocarcinoma and that these molecules are effective chemosensitizers. Though only a few trials have shown the efficacy in a clinical setting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic ductal adenocarcinoma and may help overcome chemotherapy resistance.
format	article
author	Sarah Peisl Claudia Mellenthin Lucie Vignot Carmen Gonelle-Gispert Leo Bühler Bernhard Egger
author_facet	Sarah Peisl Claudia Mellenthin Lucie Vignot Carmen Gonelle-Gispert Leo Bühler Bernhard Egger
author_sort	Sarah Peisl
title	Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
title_short	Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
title_full	Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
title_fullStr	Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
title_full_unstemmed	Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.
title_sort	therapeutic targeting of stat3 pathways in pancreatic adenocarcinoma: a systematic review of clinical and preclinical literature.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/dc7287d69a68460e8e28be95741b3bed
work_keys_str_mv	AT sarahpeisl therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature AT claudiamellenthin therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature AT lucievignot therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature AT carmengonellegispert therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature AT leobuhler therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature AT bernhardegger therapeutictargetingofstat3pathwaysinpancreaticadenocarcinomaasystematicreviewofclinicalandpreclinicalliterature
_version_	1718413831643856896

Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.

Ejemplares similares